Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Metastatic Breast Cancer Subjects
The purpose of this study is to compare active immunotherapy (OPT-822/OPT-821) with PBS in combination with low dose cyclophosphamide, in post-treated metastatic breast cancer subjects with stable disease or response to treatment.
Metastatic Breast Cancer
BIOLOGICAL: OPT-822/OPT-821(30 μg/100 μg)|BIOLOGICAL: Phosphate Buffer Saline (PBS)|DRUG: Cyclophosphamide
Progression Free Survival (PFS), Progression or up to 2 years
Overall Survival (OS), 5 years
The purpose of this study is to compare active immunotherapy (OPT-822/OPT-821) with PBS in combination with low dose cyclophosphamide, in post-treated metastatic breast cancer subjects with stable disease or response to treatment.